Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...

It has a market cap of $523 billion, significantly lower than Visa and Eli Lilly. However, the stock is exchanging hands for $1,228 and is up 90% in 12 months.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...